Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

While overall clinical trial activity appears to be slowing, June was the busiest month for the year, and, in fact, all of last year, with a total of 436 items of news related to phase I, phase II and phase III research.

Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

These graphs compare the performance of the biotech stocks for all of 2021 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.